In the latest installment of The Wire’s Company in the News feature, we are looking at Hengrui Pharma, or Jiangsu Hengrui Medicine Company, one of China’s leading pharmaceutical firms driving research and production of innovative drugs. Hengrui’s chairman is famous for taking the company from a state-owned enterprise in 1970 to a $1.5 billion IPO in 2025, but perhaps even more so for his family: His wife is the billionaire founder and CEO of Jiangsu-based Hansoh Pharma, and his daughter is
Subscribe or login to read the rest.
Subscribers get full access to:
- Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
- A weekly curated reading list on China from Andrew Peaple.
- A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our
Subscriptions page for details.
Includes images from Depositphotos.com
